Startup profile · funding coverage
Esperion Therapeutics funding, valuation and investors
Public biotech developing oral non-statin LDL-cholesterol therapies (NEXLETOL/NEXLIZET).
Keep track of Esperion Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Ann Arbor, MI
Overview
Esperion Therapeutics, Inc. is a public pharmaceutical company focused on oral non-statin medicines for patients with elevated LDL cholesterol. Headquartered in Ann Arbor, Michigan; ticker NASDAQ:ESPR.
Why Esperion Therapeutics is interesting
Ann Arbor public biotech (NASDAQ:ESPR) — university-adjacent cardio-metabolic commercialization.
Key facts
- NASDAQ:ESPR
- HQ Ann Arbor, MI
- NEXLETOL / NEXLIZET franchise
Industries
Market / IPO context
Ticker: ESPR (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
FAQs about Esperion Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.